NASDAQ Market News 
TRACON Pharmaceuticals Presents Data from Phase 2 Trial of TRC102 and Temodar® in Patients with Recurrent Glioblastoma at Society for Neuro-Oncology Annual Meeting
SAN DIEGO, Nov. 19, 2018 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical ...
Adverum Announces First Patient Dosed in OPTIC Phase 1 Trial of ADVM-022 Gene Therapy in Wet Age-Related Macular Degeneration
ADVM-022 is the first intravitreally delivered gene therapy utilizing directed evolution AAV.7m8 vector for ...
Atara Biotherapeutics Announces Publication of Phase 1 Study Demonstrating Clinical Improvement in Progressive Multiple Sclerosis Patients Treated with ATA190, an Autologous Epstein-Barr Virus (EBV)-Specific T-Cell Immunotherapy
Findings reported in an article online and to be published in the December 2018 ...
2018 Vaginitis Therapeutics Market Report – Market Size is Expected to Reach USD 4.21 Billion by 2025
Dublin, Nov. 19, 2018 (GLOBE NEWSWIRE) -- The "Vaginitis Therapeutics Market Size, Share, & ...
CHMP Issues Positive Opinion on Split Dosing Regimen for DARZALEX® (daratumumab)
Media Release CHMP issued positive opinion on split dosing regimen for DARZALEX Final decision ...
Global $3.9 Bn Oligonucleotide Synthesis Market to 2025 – Strong Pipeline of Oligonucleotide Therapeutics in Clinical Trials
Dublin, Nov. 19, 2018 (GLOBE NEWSWIRE) -- The "Oligonucleotide Synthesis Market Size, Share & ...
Axsome Therapeutics to Participate in 2018 Global Mizuho Investor Conference
NEW YORK, Nov. 19, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a ...
Immunocore to co-develop IMC-C103C, a T cell redirecting bi-specific biologic, with Genentech
PRESS RELEASE Immunocore to co-develop IMC-C103C, a T cell redirecting bi-specific biologic, with Genentech ...
ContraFect to Present at Piper Jaffray Health Care Conference
YONKERS, N.Y., Nov. 19, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology ...
Immunocore to co-develop IMC-C103C, a T cell redirecting bi-specific biologic, with Genentech
PRESS RELEASE Immunocore to co-develop IMC-C103C, a T cell redirecting bi-specific biologic, with Genentech ...
BriaCell to Present Updated Clinical Data Including Early Safety Data in KEYTRUDA® Combination Study and Positive Phase IIa Monotherapy Efficacy Data at 2018 San Antonio Breast Cancer Symposium
Positive proof of concept data with Bria-IMT™ Monotherapy will highlight potent anti-tumor activity and ...
Immunocore to co-develop IMC-C103C, a T cell redirecting bi-specific biologic, with Genentech
PRESS RELEASE Immunocore to co-develop IMC-C103C, a T cell redirecting bi-specific biologic, with Genentech ...
Immunocore to co-develop IMC-C103C, a T cell redirecting bi-specific biologic, with Genentech
PRESS RELEASE Immunocore to co-develop IMC-C103C, a T cell redirecting bi-specific biologic, with Genentech ...